Tazobactum%252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination penicillin-class antibiotic with beta-lactamase inhibitory activity. Piperacillin is a broad-spectrum penicillin that inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from degradation by beta-lactamase enzymes. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Bacterial meningitis (depending on local susceptibility patterns) * Febrile neutropenia (empiric treatment) ## Adult Dosing * **Standard Dose:** 3.375 grams (3g piperacillin/0.375g tazobactam) or 4.5 grams (4g piperacillin/0.5g tazobactam) IV every 6 to 8 hours. * **Dosing Duration:** Typically 7 to 14 days, depending on indication and clinical response. * **Specific protocols for serious infections (e.g., febrile neutropenia, hospital-acquired pneumonia) may recommend higher doses or more frequent administration (e.g., 4.5 grams every 4 hours) or continuous infusions, based on local antibiograms and clinical guidelines.** ## Pediatric Dosing * **Children < 12 years:** Dosing is based on piperacillin component, typically 80 to 100 mg/kg/day divided every 6 to 8 hours. The tazobactam dose is proportional to the piperacillin dose (12.5 mg tazobactam per 100 mg piperacillin). * **Example:** For a dose of 100 mg/kg/day of piperacillin, the corresponding tazobactam dose is 12.5 mg/kg/day. This would be administered as 112.5 mg/kg/day total, divided every 6-8 hours. * **Children ≥ 12 years:** Dosed as adults. * **Dosing in neonates and infants < 1 year:** Typically 100 mg/kg/day divided every 8 to 12 hours. * **Note:** Dosing in neonates and young infants should be carefully calculated and monitored due to immature renal and hepatic function. Consult specific pediatric guidelines. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No dose adjustment needed. * CrCl 20-40 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * **Dosing for hemodialysis:** Administer usual dose every 12 hours and administer an additional dose after each dialysis session. * **Hepatic Impairment:** No specific dose adjustment is typically recommended, but caution is advised. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, or other beta-lactam antibiotics. * History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam therapy. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, eosinophilia, elevated liver enzymes (AST, ALT), thrombocytosis. * **Serious:** * Hypersensitivity reactions, including anaphylaxis. * *Clostridioides difficile*-associated diarrhea (CDAD). * Seizures (more common with higher doses or renal impairment). * Hepatotoxicity. * Hematologic abnormalities (neutropenia, thrombocytopenia). * Interstitial nephritis. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations. * **Aminoglycosides:** Concurrent administration may lead to synergistic or additive bactericidal activity. However, *in vitro* inactivation of piperacillin by aminoglycosides can occur, and they should generally not be mixed in the same IV line. * **Vecuronium:** Piperacillin may prolong the neuromuscular blockade of vecuronium. * **Warfarin:** May decrease the anticoagulant effect of warfarin; closer INR monitoring is advised. ## Monitoring * **Renal function** (especially in patients with known renal impairment or those receiving nephrotoxic agents). * **Liver function tests** (baseline and periodically). * **Complete blood count** (baseline and periodically, especially with prolonged therapy or risk factors for hematologic effects). * **Signs and symptoms of infection** and clinical response. * **Signs of hypersensitivity reactions.** * **Stool for *C. difficile*** if diarrhea develops. ## Clinical Pearls * Piperacillin-tazobactam is a broad-spectrum agent useful for empiric therapy in moderate to severe infections, particularly those involving Gram-negative organisms and anaerobes, and in hospital-acquired infections. * The risk of seizures is increased with renal impairment and higher doses. * Dilute reconstituted solution to avoid vein irritation. Administer IV over at least 30 minutes. * Avoid co-administration of piperacillin-tazobactam with aminoglycosides in the same infusion due to potential inactivation. If concomitant therapy is indicated, administer separately. * Ensure adequate hydration to minimize the risk of crystalluria. *** **Disclaimer:** This information is for educational purposes only and does not constitute medical advice. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions.